Medpace Holdings, Inc. (NASDAQ:MEDP) Receives $491.27 Consensus Target Price from Analysts

Medpace Holdings, Inc. (NASDAQ:MEDP) has earned a consensus rating of “Reduce” from the fifteen ratings firms that are currently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and two have assigned a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $491.2727.

Several equities analysts have recently weighed in on MEDP shares. TD Cowen restated a “sell” rating on shares of Medpace in a research report on Friday, October 24th. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a report on Friday, October 31st. Wall Street Zen raised shares of Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Robert W. Baird set a $613.00 target price on shares of Medpace in a report on Friday, October 24th. Finally, Zacks Research downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th.

Insider Transactions at Medpace

In related news, CEO August J. Troendle sold 59,025 shares of the stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $607.78, for a total value of $35,874,214.50. Following the completion of the transaction, the chief executive officer directly owned 774,602 shares in the company, valued at approximately $470,787,603.56. This represents a 7.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Susan E. Burwig sold 20,000 shares of the firm’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the sale, the vice president directly owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. This trade represents a 42.11% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 341,695 shares of company stock worth $205,718,239 in the last ninety days. Insiders own 20.30% of the company’s stock.

Hedge Funds Weigh In On Medpace

A number of hedge funds have recently modified their holdings of the business. Quent Capital LLC purchased a new stake in Medpace in the 3rd quarter valued at about $25,000. Optiver Holding B.V. acquired a new stake in shares of Medpace during the third quarter valued at about $27,000. Geneos Wealth Management Inc. increased its position in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Medpace in the 4th quarter valued at approximately $30,000. Finally, Quarry LP acquired a new position in shares of Medpace in the 3rd quarter worth approximately $35,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Stock Down 0.7%

MEDP opened at $597.91 on Thursday. Medpace has a twelve month low of $250.05 and a twelve month high of $628.92. The company has a market cap of $16.84 billion, a PE ratio of 41.81, a price-to-earnings-growth ratio of 2.02 and a beta of 1.43. The company has a 50-day moving average price of $584.33 and a 200 day moving average price of $527.06.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.